IP Library › Granted Patent US 12,268,690
Granted Patent B2
US 12,268,690 · App. 17/263,531 · Granted Apr 8, 2025

Treatments for mutations in acute myeloid leukemia

Inventors: Jeffrey W Tyner (Portland, OR); Cristina Tognon (Portland, OR); Brian J Druker (Portland, OR); Daniel Bottomly (Beaverton, OR); Beth Wilmot (Portland, OR); Stephen Kurtz (Portland, OR); Samantha Savage Stevens (Portland, OR); Nicola Long (Portland, OR); Anna Reister Schultz (Beaverton, OR); Elie Traer (Portland, OR); Shannon K McWeeney (Portland, OR)
Assignee: Oregon Health & Science University
A61K31/519C12Q1/6886C12Q2600/106C12Q2600/156C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,690
App. No.
17/263,531
Granted
Apr 8, 2025
Kind
B2
Abstract

The present invention relates to useful methods of treating Acute Myeloid Leukemia (AML) in a human. in the presence of gene mutations.

Claims (5)

1. A method of treating Acute Myeloid Leukemia in a human, wherein the Acute Myeloid Leukemia is characterized by a mutation at least in the NPM1 gene, the method comprising administering to the human in need thereof a therapeutically effective amount of ibrutinib, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the Acute Myeloid Leukemia is further characterized by a mutation in the DNMT3A gene.

3. The method of claim 1 , wherein the Acute Myeloid Leukemia is further characterized by a mutation in the FLT3 gene.

4. The method of claim 1 , wherein the Acute Myeloid Leukemia is further characterized by mutations in the DNMT3A and FLT3 genes.

5. The method of claim 1 , wherein ibrutinib is administered to the human in need thereof at a dose of from about 50 mg to about 1200 mg once or twice daily.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2025
From: TYNER, JEFFREY W.; BOTTOMLY, DANIEL; WILMOT, BETH; KURTZ, STEPHEN E.; LONG, NICOLA; REISTER SCHULTZ, ANNA; TRAER, ELIE; MCWEENEY, SHANNON K.; SAVAGE STEVENS, SAMANTHA
To: OREGON HEALTH & SCIENCE UNIVERSITY
Reel/Frame 070441/0252 →
Continuity (3)
Provisional Application 62711452 · Jul 27, 2018
Related Publication 20210235374A1 · Jul 29, 2021
Related Publication 20240033265A2 · Feb 1, 2024
References Cited (57)
US 10111882B2 · Abella · 2018 [cited by applicant]
US 20160166579A1 · Di Paolo · 2016 [cited by applicant]
US 20170157132A1 · Wu · 2017 [cited by applicant]
US 20170232030A1 · Klaus · 2017 [cited by applicant]
US 20180117031A1 · Jain · 2018 [cited by applicant]
US 20180153975A1 · Fritsch · 2018 [cited by applicant]
US 20200054639A1 · Tyner · 2020 [cited by applicant]
US 20200338088A1 · Nesterovitch · 2020 [cited by applicant]
WO WO2016065674A1 · 2016 [cited by examiner]
WO WO2018081830A9 · 2018 [cited by examiner]
English translation of WO 2016/065674 A1 (Year: 2016). [cited by examiner]
The PCT Search Report and Written Opinion mailed Oct. 11, 2019 for PCT application No. PCT/US2019/043759, 20 pages. [cited by applicant]
Kottaridis, P. D. et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle o… [cited by applicant]
Dohner, K. et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106, 3740-3746, doi:10.1182/… [cited by applicant]
Falini, B. et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 109, 874-885, doi:10.1182/blood-2006-07-012252 (2007). [cited by applicant]
Huang, Q. et al. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol 142, 489-492, doi:10.1111/j.1365-2141.2008.07205.x (2008). [cited by applicant]
Wouters, B. J. et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. … [cited by applicant]
Kurtz, S. E. et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A 114, E7554-E7563, doi:10.1073/pnas.1703… [cited by applicant]
Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374, 2209-2221, doi:10.1056/NEJMoa1516192 (2016). [cited by applicant]
Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391-2405, doi:10.1182/blood-2016-03-643544 (2016). [cited by applicant]
Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424-447, doi:10.1182/blood-2016-08-733196 (2017). [cited by applicant]
TCGA. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368, 2059-2074, doi:10.1056/NEJMoa1301689 (2013). [cited by applicant]
Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366, 1079-1089, doi:10.1056/NEJMoa1112304 (2012). [cited by applicant]
Lundberg, P. et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123, 2220-2228, doi:10.1182/blood-2013-11-537167 (2014). [cited by applicant]
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371, 2477-2487, doi:10.1056/NEJMoa1409405 (2014). [cited by applicant]
Tse, K. F. et al. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14, 1766-1776 (2000). [cited by applicant]
Yamamoto, Y. et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97, 2434-2439 (2001). [cited by applicant]
Yokota, S. et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patient… [cited by applicant]
Knapper, S. et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108, 3262-3270, … [cited by applicant]
Ofarrell, A. M. et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9, 5465-5476 (2003). [cited by applicant]
Smith, B. D. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669-3676, doi:10.1182/blood-2003-11-3775… [cited by applicant]
Deangelo, D. J. et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmac… [cited by applicant]
Stone, R. M. et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377, 454-464, doi:10.1056/NEJMoa1614359 (2017). [cited by applicant]
Smith, C. C. et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485, 260-263, doi:nature11016 [pii]10.1038/nature11016 (2012). [cited by applicant]
Shih, A. H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502-515, doi:10.1016/j.ccell.2015.03.009 (2015). [cited by applicant]
Sato, T. et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117, 3286-3293, doi:10.1182/blood-2010-01-266742 (2011). [cited by applicant]
Traer, E. et al. FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Res, doi:10.1158/0008-5472.can-15-3569 (2016). [cited by applicant]
Welch, J. S. et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 375, 2023-2036, doi:10.1056/NEJMoa1605949 (2016). [cited by applicant]
Konopleva, M. et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov 6, 1106-1117, doi:10.1158/2159-8290.cd-16-0313… [cited by applicant]
Dinardo, C. D. et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lan… [cited by applicant]
Tyner, J. W. et al. Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Res 73, 285-296, doi:0008-5472.CAN-12-1906 [pii]10.1158/0008-5472.CAN-12-1906 (2013). [cited by applicant]
Puissant, A. et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 25, 226-242, doi:10.1016/j.ccr.2014.01.022 (2014). [cited by applicant]
Brinda, B. et al. The rocky road to personalized medicine in acute myeloid leukaemia. J Cell Mol Med. Mar. 2018;22(3):1411-1427. doi: 10.1111/jcmm.13478. [cited by applicant]
Choschzick, M. et al. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation. J Clin Pathol… [cited by applicant]
Guenounou, S. et al. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations. Eur J Haematol. Dec. 2014;93(6):533-6. doi: 10.1111/ejh.12334. [cited by applicant]
Heath, E. M. et al. Biological and clinical consequences of NPM1 mutations in AML. Leukemia. Apr. 2017;3(4):798-807. doi: 10.1038/leu.2017.30. [cited by applicant]
Hou, H. A. et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. Jan. 12, 2012;119(2):559-68. doi: 10.1182/blood-2011-07-369934. [cited by applicant]
Kurtz, et al. Identification of effective combinations of targeted drugs for DNMT3A and NPM1 mutated acute myeloid leukemia. Blood 2017; 130(1): 2068. [cited by applicant]
Nybakken, G. E. et al. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia. Jun. 2016;30(6):1422-5. doi: 10.1038/leu.2015.320. [cited by applicant]
Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. Dec. 16, 2010;363(25):2424-33. doi: 10.1056/NEJMoa1005143. [cited by applicant]
Nonami, A. et al. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. May 14, 2015;125(20):3133-43. doi: 10.1182/blood-2014-12-615906. [cited by applicant]
Hing, Z. A. et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia. Dec. 2016;30(12):2364-2372. doi: 10.1038/leu.2016.136. [cited by applicant]
Jain, N. et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. Jan. 15, 2014;20(2):490-8. doi: 10.1158/10… [cited by applicant]
Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. Dec. 2013;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. [cited by applicant]
Zhang, W. et al. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol Cancer Ther. Jul. 2014;13(7):1848-59. doi: 10.1158/1535-7163.MCT-13-057… [cited by applicant]
Milella, M. et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. Mar. 1, 2007;109(5):2121-9. doi: 10.1182/blood-2006-05-024679. [cited by applicant]
Wei, C.R. et al. MEK inhibitor CI-1040 induces apoptosis in acute myeloid leukemia cells in vitro. Eur Rev Med Pharmacol Sci. May 2016;20(10):1961-8. [cited by applicant]